2. Diagnosis and Investigations
Pedagogy: This lesson uses risk-stratification reasoning — distinguishing POI from early menopause and mapping each to its specific long-term health consequences and management pathway.
Learning Objectives
- Define POI (<40 years) and early menopause (40–44 years) with their diagnostic criteria
- List the principal aetiologies of POI: idiopathic, autoimmune, iatrogenic, genetic
- Describe the long-term health consequences of untreated POI
- Outline the management principles including HRT, fertility, and multidisciplinary referral
Key Facts
Definitions
| Condition | Age | Diagnostic Criteria | Prevalence |
|---|---|---|---|
| POI | <40 years | ≥4 months amenorrhoea/oligomenorrhoea + FSH >25 IU/L on two samples 4–6 weeks apart | 3.5–3.7% globally |
| Early menopause | 40–44 years | Clinical diagnosis with biochemical support if needed | ~5% of women |
Aetiology of POI
Idiopathic (majority of cases); Autoimmune (thyroid disease, Addison's, T1DM — screen for adrenal antibodies); Iatrogenic (chemotherapy, radiotherapy, bilateral oophorectomy); Genetic (Turner syndrome 45,X; FMR1 premutation; galactosaemia) (1,2).
Long-Term Health Consequences
Untreated POI is associated with increased risks of: cardiovascular disease (60% higher relative risk with surgical POI); osteoporosis and fragility fractures; cognitive decline; type 2 diabetes; and decreased life expectancy. These risks mandate hormone replacement regardless of symptom status (1,2,3).
Management Principles
The ESE guideline recommends HRT in POI irrespective of VMS or other symptoms, as multimodal benefits clearly exceed risks. HRT should continue until at least the average age of natural menopause (51 years) and then be re-evaluated. Women with POI may require higher HRT doses than those at usual menopausal age. HRT has NOT been shown to increase breast cancer risk in women under 50 beyond age-adjusted baseline (1,2).
NICE NG23 recommends offering sex steroid replacement with a choice of HRT or combined hormonal contraceptive (CHC). HRT is NOT a contraceptive — intermittent ovulation occurs in up to 25% of women with POI. All women with POI should be referred to a menopause expert and ideally a multidisciplinary team (1,2).
Clinical Pearl
HRT is recommended in ALL women with POI — even those without symptoms. The long-term cardiometabolic, skeletal, and cognitive risks of untreated oestrogen deficiency before age 40 are substantial and well-documented.
Clinical Pearl
HRT in women with POI does NOT increase breast cancer risk above age-adjusted baseline. Do not withhold treatment on the basis of breast cancer fear in this population.
Case-Based Examples
Case 1: 35-year-old with 6 months amenorrhoea
Presentation: A 35-year-old presents with 6 months of amenorrhoea, hot flushes, and low mood. She stopped the OCP 8 months ago to try to conceive. Pregnancy test negative. No relevant PMH.
Question: Outline your diagnostic pathway.
Model Answer: Suspected POI. Check FSH — if >25 IU/L, repeat in 4–6 weeks to confirm. Simultaneously check TFTs (autoimmune thyroid disease), adrenal antibodies, and consider karyotype (Turner mosaicism) and FMR1 premutation screening. Refer urgently to reproductive medicine given fertility desire. Commence HRT for long-term health protection even before fertility outcomes are known. Explain that intermittent ovulation can occur — conception may still be possible, but donor oocyte IVF may be needed.
Case 2: 37-year-old post-chemotherapy with confirmed POI
Presentation: A 37-year-old breast cancer survivor (ER-negative, completed chemotherapy 2 years ago) has confirmed POI (FSH 58 IU/L on two occasions). She has severe VMS, vaginal dryness, and is concerned about bone health. Her oncologist has confirmed HRT is not contraindicated given ER-negative status.
Question: Design a comprehensive management plan.
Model Answer: ER-negative breast cancer — HRT is not contraindicated (confirm with oncology). Start transdermal oestradiol (standard dose, she may need higher doses given young age) + micronised progesterone (she has a uterus). Aim for at least standard-dose replacement to protect bones and cardiovascular system. Add vaginal oestrogen for GSM. DEXA scan to assess bone density. Lifestyle: weight-bearing exercise, calcium 1000mg/day, vitamin D. Psychological support — referral for counselling regarding grief (fertility loss, premature ageing). Consider FMR1 and genetic testing. Annual review: HRT efficacy, DEXA at 2–3 years, cardiovascular risk factors. Continue HRT until at least age 51.
Self-Assessment Questions
PLAB/MLA Diagnostic criteria for POI
Which confirms the diagnosis of POI?
A. Single FSH >40 IU/L in a woman under 40
B. FSH >25 IU/L on two samples 4–6 weeks apart with ≥4 months amenorrhoea, aged <40
C. Undetectable AMH in a woman under 40
D. Oestradiol <100 pmol/L on a single sample
Answer: B. POI diagnosis: ≥4 months menstrual disturbance/amenorrhoea + FSH >25 IU/L confirmed on two samples 4–6 weeks apart, in a woman under 40 (ESE 2025, IMS 2025).
MRCGP HRT in asymptomatic POI
A 38-year-old with confirmed POI has no vasomotor symptoms. She asks if she really needs HRT. What is the best advice?
A. HRT only needed if symptoms develop
B. HRT recommended regardless of symptoms to prevent long-term complications, at least until age 51
C. Calcium and vitamin D are sufficient without HRT
D. HRT increases breast cancer risk and should be avoided
Answer: B. ESE 2025: HRT in POI irrespective of symptoms. Long-term risks (CVD, osteoporosis, cognitive decline, reduced life expectancy) mandate treatment until at least age 51.
Professor Genetic evaluation in POI
A 32-year-old with idiopathic POI has a daughter aged 5. What genetic testing is most important and why?
A. BRCA1/2 only
B. FMR1 premutation — carrier status affects the daughter's reproductive lifespan and has implications for fragile X syndrome in future offspring
C. Karyotype only
D. No genetic testing is required in idiopathic POI
Answer: B. FMR1 premutation (55–200 CGG repeats) is found in ~3–15% of women with non-iatrogenic POI. Carriers have earlier menopause and risk of premature ovarian ageing. Crucially, her daughter has a 50% chance of inheriting the premutation, which could expand to a full mutation (>200 repeats) in the next generation causing fragile X syndrome. Genetic counselling is essential.
Take-Away Messages
- POI (<40 years): FSH >25 IU/L on two samples 4–6 weeks apart + ≥4 months amenorrhoea
- HRT is recommended in ALL women with POI regardless of symptoms — continue until at least age 51
- POI carries increased risks of CVD, osteoporosis, cognitive decline, T2DM, and reduced life expectancy
- HRT does NOT increase breast cancer risk in women under 50 beyond age-adjusted baseline
- All women with POI should be referred to a menopause expert and multidisciplinary team